Scott Gottlieb's industry ties and potential for a conflict of interest generated wide-spread discussion upon his nomination as FDA commissioner, but other topics took center stage during his Senate confirmation hearing.
A Pink Sheet analysis of the 60 asked questions by members of the Senate Health, Education, Labor and Pensions Committee...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?